SecBot SecBot
PRESS-RELEASE ·Filed May 12, 2026

SABS

SAB Biotherapeutics, Inc.
BEARISH
Impact 7/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The significant EPS miss and widening losses are concerning, but the strong cash position and FDA endorsement of a surrogate endpoint de-risk the regulatory path. Traders should watch for SAFEGUARD enrollment updates and any partnership or licensing announcements that could validate the platform beyond T1D.

DirectionBearish
Confidencehigh
Horizonmonths

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.62
T+0 close · May 12, 2026 · via day close
Latest settled
+6.35%
T+60 · $3.85
Vs SPY
+1.97%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $3.62entry
  2. T+1 · 6mo ago +9.39%α +8.82% · $3.96
  3. T+5 · 6mo ago −1.66%α −1.74% · $3.56
  4. T+20 · 5mo ago −8.56%α −6.84% · $3.31
  5. T+60 · 3mo ago +6.35%α +1.97% · $3.85
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

SAB Biotherapeutics reported Q1 2026 EPS of -$0.35, a 68.3% miss vs consensus of -$0.21, with net loss widening to $18.9M from $5.2M a year ago. The company highlighted continued SAFEGUARD trial enrollment progress, FDA acceptance of C-peptide as a surrogate endpoint for accelerated approval, and a strong $217.6M cash position providing runway through 2028.

Key Financial Metrics

EPS
−$0.35
est −$0.21 · -66.7%
Rating
strong miss

Key Facts

  • Q1 2026 EPS of -$0.35 missed consensus of -$0.21 by 68.3%
  • Net loss widened to $18.9M from $5.2M in Q1 2025
  • R&D expenses increased to $13.4M from $7.7M YoY
  • Cash position of $217.6M at March 31, 2026, providing runway through 2028
  • Completed public offering raising $95M in gross proceeds in March 2026
  • SAFEGUARD Phase 2b trial enrollment on track for completion by end of 2026 with topline data expected in 2H 2027
  • FDA confirmed C-peptide AUC may serve as surrogate endpoint for accelerated approval
  • Phase 1 data showed C-peptide preservation and improved glycemic control in treated patients

Financial Impact

EPS miss of 68.3% vs consensus; net loss increased 263% YoY to $18.9M

epsnet lossr&d expensescash position

Risk Factors

  • Clinical trial failure or delay in SAFEGUARD could wipe out pipeline value
  • Cash burn rate is accelerating; $217.6M may not be sufficient if trials extend beyond 2028
  • Dilution risk from additional capital raises given ongoing losses
  • Competition from other T1D disease-modifying therapies (e.g., Teplizumab)

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3292726

Track record

15 reports on SABS

Performance horizon

2 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +15.67% at T+20 after the Oct 13, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
  2. Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $2.96 Now $3.00 +1.35% settles Dec 15
  3. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
  4. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $2.94 Now $3.00 +2.04% settles Dec 4
  5. Oct 22, 202625d ago 25-NSE Neutral 2/10 Entry $2.84 Now $3.00 +5.63% settles Nov 20
  6. Oct 13, 20264w ago 8-K Bullish 6/10 Entry $2.68 to $3.07 Now $3.00 +11.94% ▲ +14.55% +18.16% vs SPY
  7. Oct 13, 20264w ago Press Release Bullish 5/10 Entry $2.68 to $3.10 Now $3.00 +11.94% ▲ +15.67% +19.34% vs SPY
  8. Jul 7, 202618w ago 8-K Bullish 4/10 Entry $3.90 to $3.79 Now $3.00 −23.08% ▼ −2.82% −4.15% vs SPY
  9. May 29, 202624w ago Press Release Neutral 3/10 Entry $3.60 to $3.90 Now $3.00 −16.67% ▲ +8.33% +10.13% vs SPY
  10. May 12, 202626w ago Press Release Bearish 7/10 Viewing Entry $3.62 to $3.31 Now $3.00 +17.13% ▲ +8.56% +6.84% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026